Physician profile
Daniel Katselnik
NPI 1861674855
$601,797.50
in general payments reported to CMS, 2019-2025
86 companies · $80K in 2025
The $80K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $149K · 2020: $63K · 2021: $109K · 2022: $94K · 2023: $52K · 2024: $56K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $34K · Consulting Fee: $16K · Food and Beverage: $15K · Travel and Lodging: $15K · Gift: $59.40 · Education: $24.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108,269.40 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $33,513.00 |
| Consulting Fee | $15,640.50 |
| Food and Beverage | $14,896.41 |
| Travel and Lodging | $14,796.19 |
| Gift | $59.40 |
| Education | $24.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $325,239.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $92,742.71 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $65,553.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $47,976.47 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,397.49 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $10,890.12 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $10,310.89 | 2022-2024 | |
| Siemens Medical Solutions USA, INC. | $6,455.40 | 2025 | Atellica Im 1300 Analyzer |
| Mannkind Corporation | $5,368.35 | 2019-2025 | Afrezza |
| Insulet Corporation | $3,413.13 | 2019-2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $2,024.06 | 2022-2025 | Yorvipath |
| Amgen INC. | $1,393.36 | 2019-2025 | Repatha, Tepezza, Evenity |
| Sequel Med Tech, LLC | $862.76 | 2025 | Twiist |
| Abbvie INC. | $758.52 | 2019-2025 | |
| Antares Pharma, INC. | $685.43 | 2019-2024 | Xyosted, Nocdurna, Tlando |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $680.00 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $652.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $554.62 | 2021-2025 | |
| Cequr Corporation | $524.00 | 2022-2025 | Cequr Simplicity |
| Corcept Therapeutics | $493.95 | 2019-2025 | Korlym |
| Recordati_rare_diseases_inc. | $422.68 | 2021-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $384.50 | 2020-2023 | Gvoke Hypopen |
| Tersera Therapeutics LLC | $380.00 | 2023 | |
| Genzyme Corporation | $362.00 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $350.00 | 2022 | |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $330.00 | 2020 | |
| Ascensia Diabetes Care US INC. | $310.84 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $267.37 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $262.23 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $255.09 | 2019-2024 | Unithroid |
| Eusa Pharma (US) LLC | $214.49 | 2022 | |
| Radius Health, INC. | $181.05 | 2019-2025 | Tymlos |
| Nevro Corp. | $179.24 | 2022-2023 | Senza |
| Eisai INC. | $176.57 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.91 | 2019-2022 | |
| Esperion Therapeutics, INC. | $156.94 | 2021-2022 | |
| Kyowa Kirin, INC. | $153.67 | 2024-2025 | Crysvita |
| Shire North American Group INC | $147.83 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $143.60 | 2021-2023 | Sohonos, Somatuline Depot |
| Madrigal Pharmaceuticals | $141.41 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $135.45 | 2019-2020 | |
| Vivus LLC | $133.12 | 2019-2022 | |
| Valeritas, INC. | $119.79 | 2019 | |
| Grt US Holding, INC. | $115.70 | 2021-2022 | |
| Nalpropion Pharmaceuticals LLC | $112.18 | 2019 | |
| Intuity Medical INC | $106.97 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Beta Bionics, INC. | $103.00 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic Minimed, INC. | $101.42 | 2019-2020 | |
| Echosens North America, INC. | $99.23 | 2025 | Fibroscan |
| Merck Sharp & Dohme LLC | $96.34 | 2020-2022 | |
| Clarus Therapeutics INC. | $88.11 | 2021 | |
| Currax Pharmaceuticals LLC | $87.07 | 2020-2021 | |
| Shield Therapeutics INC | $81.94 | 2023-2025 | Accrufer |
| Acerus Pharmaceuticals Corporation | $79.62 | 2020-2022 | |
| Averitas Pharma INC. | $78.04 | 2024-2025 | Qutenza |
| Soleno Therapeutics, INC. | $72.58 | 2025 | Vykat Xr |
| Ibsa Pharma INC. | $72.01 | 2019-2023 | Tirosint, Licart |
| Amphastar Pharmaceuticals, INC. | $70.90 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $63.48 | 2023-2025 | Evkeeza, Praluent |
| Almatica Pharma LLC | $60.04 | 2025 | Teriparatide |
| Alexion Pharmaceuticals, INC. | $51.55 | 2020-2025 | Strensiq |
| Medtronic, INC. | $46.53 | 2022-2023 | Minimed 780g |
| Becton, Dickinson and Company | $42.74 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $35.34 | 2021-2022 | |
| Astellas Pharma US INC | $34.15 | 2023-2024 | Veozah |
| Pfizer INC. | $33.15 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.60 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $31.65 | 2025 | |
| Companion Medical, INC. | $31.55 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $31.42 | 2025 | Imcivree |
| Ionis Pharmaceuticals, INC. | $26.19 | 2025 | Tryngolza |
| Rgh Enterprises LLC | $24.00 | 2025 | |
| Vistapharm, INC. | $23.14 | 2021 | |
| Althera Pharmaceuticals LLC | $21.34 | 2021 | |
| Janssen Scientific Affairs, LLC | $19.22 | 2019 | |
| Acella Pharmaceuticals, LLC | $18.71 | 2025 | NP Thyroid 60 |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Lifescan, INC. | $15.55 | 2019 | |
| Halozyme INC | $15.15 | 2023 | |
| Itamar Medical INC | $14.64 | 2022 | |
| Strongbridge US INC. | $13.54 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.42 | 2023 | |
| Bigfoot Biomedical INC | $12.57 | 2021 | |
| Senseonics, Incorporated | $10.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$110,005.33 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Katselnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.